Anti-VEGF agents for ocular angiogenesis and vascular permeability

Journal of Ophthalmology

Volumn 2012, Issue , 2012, Pages

  Kimoto, Kenichi ^a   Kubota, Toshiaki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869435259     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2012/852183     Document Type: Review

References (103)

1. Rosenfeld P. J., Brown D. M., Heier J. S., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 (Pubitemid 44511557)
2. Brown D. M., Michels M., Kaiser P. K., Heier J. S., Sy J. P., Ianchulev T., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009 116 1 57 65 2-s2.0-57949094834 10.1016/j.ophtha.2008.10.018
3. Regillo C. D., Brown D. M., Abraham P., Yue H., Ianchulev T., Schneider S., Shams N., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. American Journal of Ophthalmology 2008 145 2 239 248 2-s2.0-38349172455 10.1016/j.ajo.2007.10.004
4. Abraham P., Yue H., Wilson L., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology 2010 150 3 315 324 2-s2.0-77956056292 10.1016/j.ajo.2010.04.011
5. Fung A. E., Lalwani G. A., Rosenfeld P. J., Dubovy S. R., Michels S., Feuer W. J., Puliafito C. A., Davis J. L., Flynn H. W., Esquiabro M., An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 143 4 566 583 2-s2.0-33947403618 10.1016/j.ajo.2007.01.028 (Pubitemid 46452533)
6. Lalwani G. A., Rosenfeld P. J., Fung A. E., Dubovy S. R., Michels S., Feuer W., Davis J. L., Flynn H. W., Esquiabro M., A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. American Journal of Ophthalmology 2009 148 1 43 58 2-s2.0-67149101784 10.1016/j.ajo.2009.01.024
7. Chakravarthy U., Adamis A. P., Cunningham E. T. Jr., Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006 113 9 1508 1525
8. Friberg T. R., friberg@pitt.edu Tolentino M., Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. British Journal of Ophthalmology 2010 94 12 1611 1617 10.1136/bjo.2009.174946
9. Martin D. F., Maguire M. G., maguirem@mail.med.upenn.edu Ying G.-S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011 364 20 1897 1908 10.1056/NEJMoa1102673
10. Heier J. S., Boyer D., Nguyen Q. D., Marcus D., Roth D. B., Yancopoulos G., Stahl N., Ingerman A., Vitti R., Berliner A. J., Yang K., Brown D. M., dmbmd@houstonretina.com The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011 118 6 1098 1106 10.1016/j.ophtha.2011.03.020
11. Campochiaro P. A., Hafiz G., Shah S. M., Nguyen Q. D., Ying H., Do D. V., Quinlan E., Zimmer-Galler I., Haller J. A., Solomon S. D., Sung J. U., Hadi Y., Janjua K. A., Jawed N., Choy D. F., Arron J. R., Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy 2008 16 4 791 799 2-s2.0-41149085598 10.1038/mt.2008.10 (Pubitemid 351426182)
12. Spaide R. F., Chang L. K., Klancnik J. M., Yannuzzi L. A., Sorenson J., Slakter J. S., Freund K. B., Klein R., Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. American Journal of Ophthalmology 2009 147 2 298 306 2-s2.0-58349122638 10.1016/j.ajo.2008.08.016
13. Pieramici D. J., Rabena M., Castellarin A. A., Nasir M., See R., Norton T., Sanchez A., Risard S., Avery R. L., Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008 115 10 e47 e54 2-s2.0-52949116090 10.1016/j.ophtha.2008.06.021
14. Brown D. M., Campochiaro P. A., Singh R. P., Li Z., Gray S., Saroj N., Rundle A. C., Rubio R. G., Murahashi W. Y., Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 2010 117 6 1124 1133 2-s2.0-77952889477 10.1016/j.ophtha.2010.02.022
15. Campochiaro P. A., pcampo@jhmi.edu Brown D. M., Awh C. C., Lee S. Y., Gray S., Saroj N., Murahashi W. Y., Rubio R. G., Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011 118 10 2041 2049 10.1016/j.ophtha.2011.02.038
16. Campochiaro P. A., Heier J. S., Feiner L., Gray S., Saroj N., Rundle A. C., Murahashi W. Y., Rubio R. G., Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 2010 117 6 1102 e1 2-s2.0-77952891051 10.1016/j.ophtha. 2010.02.021
17. Brown D. M., Campochiaro P. A., Bhisitkul R. B., Ho A. C., Gray S., Saroj N., Adamis A. P., Rubio R. G., Murahashi W. Y., Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011 118 8 1594 1602
18. Do D. V., ddo@jhmi.edu Schmidt-Erfurth U., Gonzalez V. H., Gordon C. M., Tolentino M., Berliner A. J., Vitti R., Rückert R., Sandbrink R., Stein D., Yang K., Beckmann K., Heier J. S., The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011 118 9 1819 1826 10.1016/j.ophtha.2011.02.018
19. Avery R. L., Pearlman J., Pieramici D. J., Rabena M. D., Castellarin A. A., Nasir M. A., Giust M. J., Wendel R., Patel A., Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006 113 10 1695 1705 2-s2.0-33748982649 10.1016/j.ophtha.2006.05.064 (Pubitemid 44442453)
20. Bakri S. J., Donaldson M. J., Link T. P., Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 2006 20 12 1474 1475 2-s2.0-33745348133 10.1038/sj.eye.6702364 (Pubitemid 44921215)
21. Mason J. O., Nixon P. A., White M. F., Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. American Journal of Ophthalmology 2006 142 4 685 688 2-s2.0-33748985366 10.1016/j.ajo.2006.04.058 (Pubitemid 44442055)
22. Spaide R. F., Fisher Y. L., Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006 26 3 275 278 2-s2.0-33646464279 10.1097/00006982-200603000-00004 (Pubitemid 44318179)
23. Wu L., Martínez-Castellanos M. A., Quiroz-Mercado H., Arevalo J. F., Berrocal M. H., Farah M. E., Maia M., Roca J. A., Rodriguez F. J., Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES). Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 1 81 87 2-s2.0-36448993366 10.1007/s00417-007-0660-z (Pubitemid 350167096)
24. Avery R. L., Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment. Retina 2006 26 3 352 354 2-s2.0-33646447443 10.1097/00006982-200603000-00016 (Pubitemid 44318195)
25. Davidorf F. H., Mouser J. G., Derick R. J., Rapid improvement of rubeosis iridis from a single bevacizumab (avastin) injection. Retina 2006 26 3 354 356 2-s2.0-33646455655 10.1097/00006982-200603000-00017 (Pubitemid 44318196)
26. Kahook M. Y., Schuman J. S., Noecker R. J., Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surgery Lasers and Imaging 2006 37 2 144 146 2-s2.0-33645529490
27. Grisanti S., salvatore.grisanti@med.uni-tuebingen.de Biester S., Peters S., Tatar O., Ziemssen F., Bartz-Schmidt K. U., Intracameral bevacizumab for Iris rubeosis. American Journal of Ophthalmology 2006 142 1 158 160 10.1016/j.ajo.2006.02.045 (Pubitemid 43946796)
28. Oshima Y., Sakaguchi H., Gomi F., Tano Y., Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. American Journal of Ophthalmology 2006 142 1 155 158 2-s2.0-33745392312 10.1016/j.ajo.2006.02.015 (Pubitemid 43946776)
29. Iliev M. E., Domig D., Wolf-Schnurrbursch U., Wolf S., Sarra G. M., Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. American Journal of Ophthalmology 2006 142 6 1054 1056 2-s2.0-33845227094 10.1016/j.ajo.2006.06.066 (Pubitemid 44853889)
30. Yazdani S., Hendi K., Pakravan M., Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. Journal of Glaucoma 2007 16 5 437 439 2-s2.0-34547911371 10.1097/IJG.0b013e3180457c47 (Pubitemid 47263045)
31. Mason J. O., Albert M. A., Mays A., Vail R., Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006 26 7 839 841 2-s2.0-33748650814 10.1097/01.iae.0000230425.31296.3b (Pubitemid 44386115)
32. Yazdani S., Hendi K., Pakravan M., Mahdavi M., Yaseri M., Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. Journal of Glaucoma 2009 18 8 632 637 2-s2.0-73349099706 10.1097/IJG.0b013e3181997211
33. Rizzo S., Genovesi-Ebert F., Bartolo E., Vento A., Miniaci S., Williams G., Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 6 837 842 2-s2.0-43549104713 10.1007/s00417-008-0774-y
34. Schmidinger G., gerald.schmidinger@meduniwien.ac.at Maar N., Bolz M., Scholda C., Schmidt-Erfurth U., Repeated intravitreal bevacizumab (AvastinÂ) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmologica 2011 89 1 76 81 10.1111/j.1755-3768.2009.01622.x
35. Wakabayashi T., Oshima Y., Sakaguchi H., Ikuno Y., Miki A., Gomi F., Otori Y., Kamei M., Kusaka S., Tano Y., Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008 115 9 1571 1580 2-s2.0-50249138759 10.1016/j.ophtha.2008.02.026
36. Saito Y., Higashide T., Takeda H., Murotani E., Ohkubo S., Sugiyama K., Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab. American Journal of Ophthalmology 2010 149 6 964 972 2-s2.0-77952553025 10.1016/j.ajo.2010.01.008
37. Takihara Y., Inatani M., Kawaji T., Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. Journal of Glaucoma 2011 20 3 196 201
38. Saito Y., Higashide T., Takeda H., Ohkubo S., Sugiyama K., Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmologica 2010 88 1 96 102 2-s2.0-76149092470 10.1111/j.1755-3768.2009.01648.x
39. Chen E., Park C. H., Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006 26 6 699 700 2-s2.0-33747335983 10.1097/01.iae.0000225351.87205.69 (Pubitemid 44620378)
40. Ishikawa K., Honda S., Tsukahara Y., Negi A., Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009 23 1 108 111 2-s2.0-58249102934 10.1038/sj.eye.6702983
41. Da Lucena D. R., Ribeiro J. A. S., Costa R. A., Barbosa J. C., Scott I. U., De Figueiredo-Pontes L. L., Jorge R., Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). British Journal of Ophthalmology 2009 93 5 688 691 2-s2.0-66149143624 10.1136/bjo.2008.151233
42. Peters S., Swaantje.Peters@googlemail.com Heiduschka P., Julien S., Ziemssen F., Fietz H., Bartz-Schmidt K. U., Schraermeyer U., Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. American Journal of Ophthalmology 2007 143 6 995 1002 10.1016/j.ajo.2007.03.007 (Pubitemid 46764670)
43. Marneros A. G., Fan J., Yokoyama Y., Gerber H. P., Ferrara N., Crouch R. K., Olsen B. R., Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. American Journal of Pathology 2005 167 5 1451 1459 2-s2.0-27544442148 (Pubitemid 41541430)
44. Roberts W. G., Palade G. E., Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. Journal of Cell Science 1995 108 6 2369 2379 2-s2.0-0029010434
45. Dastjerdi M. H., Al-Arfaj K. M., Nallasamy N., Hamrah P., Jurkunas U. V., Pineda R., Pavan-Langston D., Dana R., Topical bevacizumab in the treatment of corneal neovascularization; results of a prospective, open-label, noncomparative study. Archives of Ophthalmology 2009 127 4 381 389 2-s2.0-65249103986 10.1001/archophthalmol.2009.18
46. Koenig Y., Bock F., Horn F., Kruse F., Straub K., Cursiefen C., Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology 2009 247 10 1375 1382 2-s2.0-69549112893 10.1007/s00417-009-1099-1
47. Vassileva P. I., Hergeldzhieva T. G., Avastin use in high risk corneal transplantation. Graefe's Archive for Clinical and Experimental Ophthalmology 2009 247 12 1701 1706 2-s2.0-71449087265 10.1007/s00417-009-1170-y
48. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E., Nguyen H. V., Aiello L. M., Ferrara N., King G. L., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine 1994 331 22 1480 1487 2-s2.0-0027942607 10.1056/NEJM199412013312203 (Pubitemid 24356306)
49. Pe'er J., Folberg R., Itin A., Gnessin H., Hemo I., Keshet E., Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998 105 3 412 416 2-s2.0-0031940281 10.1016/S0161-6420(98)93020-2 (Pubitemid 28125092)
50. Moss S. E., Klein R., Klein B. E. K., Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994 101 6 1061 1070 2-s2.0-0028275559 (Pubitemid 24183163)
51. Paulus Y. M., Gariano R. F., Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009 64 2 16 20 2-s2.0-63049133469
52. Klein R., Knudtson M. D., Lee K. E., Gangnon R., Klein B. E. K., The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twentyfive- year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009 116 3 497 503 2-s2.0-61349121337 10.1016/j.ophtha.2008.10.016
53. Nguyen Q. D., Shah S. M., Van Anden E., Sung J. U., Vitale S., Campochiaro P. A., Supplemental oxygen improves diabetic macular edema: a pilot study. Investigative Ophthalmology and Visual Science 2004 45 2 617 624 2-s2.0-0942265576 10.1167/iovs.03-0557 (Pubitemid 38140522)
54. Vinores S. A., Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histology and Histopathology 1997 12 1 99 109 (Pubitemid 27106924)
55. Derevjanik N. L., Vinores S. A., Xiao W. H., Mori K., Turon T., Hudish T., Dong S., Campochiaro P. A., Quantitative assessment of the integrity of the blood-retinal barrier in mice. Investigative Ophthalmology and Visual Science 2002 43 7 2462 2467 2-s2.0-0036295180 (Pubitemid 34700682)
56. Ozaki H., Hayashi H., Vinores S. A., Moromizato Y., Campochiaro P. A., Oshima K., Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Experimental Eye Research 1997 64 4 505 517 2-s2.0-0031126380 10.1006/exer.1996.0239 (Pubitemid 27321334)
57. Massin P., Bandello F., Garweg J. G., Hansen L. L., Harding S. P., Larsen M., Mitchell P., Sharp D., Wolf-Schnurrbusch U. E. K., Gekkieva M., Weichselberger A., Wolf S., sebastian.wolf@insel.ch Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010 33 11 2399 2405 10.2337/dc10-0493
58. Mitchell P., paul.mitchell@sydney.edu.au Bandello F., Schmidt-Erfurth U., Lang G. E., Massin P., Schlingemann R. O., Sutter F., Simader C., Burian G., Gerstner O., Weichselberger A., The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011 118 4 615 625 10.1016/j.ophtha.2011.01.031
59. Nguyen Q. D., Shah S. M., Heier J. S., Do D. V., Lim J., Boyer D., Abraham P., Campochiaro P. A., Primary end point (Six Months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009 116 11 2175 2181 2-s2.0-70350567637 10.1016/j.ophtha.2009.04.023
60. Nguyen Q. D., Shah S. M., Khwaja A. A., Channa R., Hatef E., Do D. V., Boyer D., Heier J. S., Abraham P., Thach A. B., Lit E. S., Foster B. S., Kruger E., Dugel P., Chang T., Das A., Ciulla T. A., Pollack J. S., Lim J. I., Eliot D., Campochiaro P. A., Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010 117 11 2146 2151 2-s2.0-78049293726 10.1016/j.ophtha.2010.08.016
61. Johnson M., Gong H., Freddo T. F., Ritter N., Kamm R., Serum proteins and aqueous outflow resistance in bovine eyes. Investigative Ophthalmology and Visual Science 1993 34 13 3549 3557 2-s2.0-0027759379 (Pubitemid 24011991)
62. Gartner S., Henkind P., Neovascularization of the iris (Rubeosis iridis). Survey of Ophthalmology 1978 22 5 291 312 2-s2.0-0017799259 (Pubitemid 8318531)
63. Kubota T., Tawara A., Hata Y., Khalil A., Inomata H., Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma. British Journal of Ophthalmology 1996 80 8 750 754 2-s2.0-0029787792 (Pubitemid 26334921)
64. Peters S., swaantje.peters@googlemail.com Heiduschka P., Julien S., Bartz-Schmidt K.-U., Schraermeyer U., Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. British Journal of Ophthalmology 2008 92 4 541 544 10.1136/bjo.2007.133496 (Pubitemid 351497987)
65. Ishibashi S., Tawara A., Sohma R., Kubota T., Toh N., Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. Archives of Ophthalmology 2010 128 12 1539 1545 2-s2.0-78650114110 10.1001/archophthalmol.2010.282
66. Kubota T., Aoki R., Harada Y., Tou N., Kohno Y., Tawara A., Satoh H., Shimajiri S., Trabecular meshwork in neovascular glaucoma eyes after the intravitreal injection of bevacizumab. British Journal of Ophthalmology 2009 93 4 557 558 2-s2.0-64849103131 10.1136/bjo.2008.148148
67. Kohno R. I., Hata Y., Mochizuki Y., Arita R., Kawahara S., Kita T., Miyazaki M., Hisatomi T., Ikeda Y., Aiello L. P., Ishibashi T., Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. American Journal of Ophthalmology 2010 150 2 223 229 2-s2.0-77955474539 10.1016/j.ajo.2010.03.016
68. Sawada O., Kawamura H., Kakinoki M., Sawada T., Ohji M., Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Archives of Ophthalmology 2007 125 10 1363 1366 2-s2.0-35349022642 10.1001/archopht.125.10. 1363 (Pubitemid 47606601)
69. Folkman J., Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine 1971 285 21 1182 1186 2-s2.0-0015231516
70. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004 25 4 581 611 2-s2.0-4143136640 10.1210/er.2003-0027 (Pubitemid 39099316)
71. Adamis A. P., Shima D. T., The role of vascular endothelial growth factor in ocular health and disease. Retina 2005 25 2 111 118 2-s2.0-14944361800 10.1097/00006982-200502000-00001 (Pubitemid 40365933)
72. Murata T., Nakagawa K., Khalil A., Ishibashi T., Inomata H., Sueishi K., The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Laboratory Investigation 1996 74 4 819 825 2-s2.0-0029918128 (Pubitemid 26117141)
73. Funatsu H., Yamashita H., Noma H., Mimura T., Nakamura S., Sakata K., Hori S., Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefe's Archive for Clinical and Experimental Ophthalmology 2005 243 1 3 8 2-s2.0-12444278290 10.1007/s00417-004-0950-7
74. Wallow I. H. L., Geldner P. S., Endothelial fenestrae in proliferative diabetic retinopathy. Investigative Ophthalmology and Visual Science 1980 19 10 1176 1183 2-s2.0-0019269001 (Pubitemid 11050773)
75. Ahmadieh H., Shoeibi N., Entezari M., Monshizadeh R., Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009 116 10 1943 1948 2-s2.0-70349440840 10.1016/j.ophtha.2009.07.001
76. Kuiper E. J., Van Nieuwenhoven F. A., de Smet M. D., van Meurs J. C., Tanck M. W., Oliver N., Klaassen I., Van Noorden C. J. F., Goldschmeding R., Schlingemann R. O., The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 2008 3 7 2-s2.0-50549089040 10.1371/journal.pone. 0002675 e2675
77. Moradian S., Ahmadieh H., Malihi M., Sohellian M., Dehgan M. H., Azarmina M., Intravitreal bevacizumab in active progressive in active progressive proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 12 1699 1705
78. Arevalo J. F., Maia M., Flynn H. W., Saravia M., Avery R. L., Wu L., Eid Farah M., Pieramici D. J., Berrocal M. H., Sanchez J. G., Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. British Journal of Ophthalmology 2008 92 2 213 216 2-s2.0-38949099070 10.1136/bjo.2007.127142 (Pubitemid 351224097)
79. Kubota T., Morita H., Tou N., Nitta N., Tawara A., Satoh H., Shimajiri S., Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Retina 2010 30 3 468 472 2-s2.0-77949419018 10.1097/IAE.0b013e3181bd2d7b
80. El-Sabagh H. A., Abdelghaffar W., Labib A. M., Mateo C., Hashem T. M., Al-Tamimi D. M., Selim A. A., Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 2011 118 4 636 641 2-s2.0-78049321698 10.1016/j.ophtha.2010.08.038
81. Repka M. X., Tung B., Good W. V., Shapiro M., Capone A., Baker J. D., Barr C. C., Phelps D. L., Van Heaven W. A. J., Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Archives of Ophthalmology 2006 124 1 24 30 2-s2.0-30344470460 10.1001/archopht.124.1.24 (Pubitemid 43063885)
82. Gilbert W. S., Quinn G. E., Dobson V., Reynolds J., Hardy R. J., Palmer E. A., Partial retinal detachment at 3 months after threshold retinopathy of prematurity: long-term structural and functional outcome. Archives of Ophthalmology 1996 114 9 1085 1091
83. Good W. V., Flynn J. T., Flach A. J., Cibis G. W., Raab E. L., Beauchamp G. R., Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Transactions of the American Ophthalmological Society 2004 102 233 250 (Pubitemid 40706105)
84. Chung E. J., Kim J. H., Ahn H. S., Koh H. J., Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity. Graefe's Archive for Clinical and Experimental Ophthalmology 2007 245 11 1727 1730 2-s2.0-34848909008 10.1007/s00417-007-0661-y (Pubitemid 47491565)
85. Mintz-Hittner H. A., Kuffel R. R., Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone i or posterior zone II. Retina 2008 28 6 831 838 2-s2.0-47749100480 10.1097/IAE.0b013e318177f934
86. Quiroz-Mercado H., Martinez-Castellanos M. A., Hernandez-Rojas M. L., Salazar-Teran N., Chan R. V. P., Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008 28 3 S19 S25 2-s2.0-43149109737 10.1097/IAE.0b013e318159ec6b (Pubitemid 351644419)
87. Lalwani G. A., Berrocal A. M., Murray T. G., Buch M., Cardone S., Hess D., Johnson R. A., Puliafito C. A., Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008 28 3 S13 S18 2-s2.0-43149101294 10.1097/IAE. 0b013e3181644ad2 (Pubitemid 351644418)
88. Kusaka S., Shima C., Wada K., Arahori H., Shimojyo H., Sato T., Fujikado T., Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. British Journal of Ophthalmology 2008 92 11 1450 1455 2-s2.0-55449105439 10.1136/bjo.2008.140657
89. Micieli J. A., Surkont M., Smith A. F., A systemic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. American Journal of Ophthalmology 2009 148 4 536 543 2-s2.0-70349296781 10.1016/j.ajo.2009.05.031
90. Sato T., Kusaka S., Shimojo H., Fujikado T., Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009 116 9 1599 1603 2-s2.0-69249174238 10.1016/j.ophtha.2008.12.023
91. Nonobe N. I., Kachi S., Kondo M., Takai Y., Takemoto K., Nakayama A., Hayakawa M., Terasaki H., Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 2009 29 5 579 585 2-s2.0-66349135966 10.1097/IAE.0b013e3181a3b848
92. Nazari H., Modarres M., Parvaresh M. M., Ghasemi Falavarjani K., Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 248 12 1713 1718 2-s2.0-78549266120 10.1007/s00417-010-1430-x
93. Wu W. C., Yeh P. T., Chen S. N., Yang C. M., Lai C. C., Kuo H. K., Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011 118 1 176 183 2-s2.0-78650837171 10.1016/j.ophtha.2010.04.018
94. Lee J. Y., Chae J. B., Yang S. J., Yoon Y. H., Kim J. G., Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 248 9 1257 1262 2-s2.0-77955558845 10.1007/s00417-010-1375-0
95. Hoang Q. V., Kiernan D. F., Chau F. Y., Shapiro M. J., Blair M. P., Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Archives of Ophthalmology 2010 128 8 1080 1081 2-s2.0-77955443049 10.1001/archophthalmol.2010.145
96. Kychenthal A., Dorta P., Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina 2010 30 4 S32 S36 2-s2.0-77951093728 10.1097/IAE.0b013e3181ca146b
97. Honda S., Hirabayashi H., Tsukahara Y., Negi A., Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 7 1061 1063 2-s2.0-44649085756 10.1007/s00417-008-0786-7
98. Saint-Geniez M., Maharaj A. S. R., Walshe T. E., Tucker B. A., Sekiyama E., Kurihara T., Darland D. C., Young M. J., D'Amore P. A., Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 2008 3 11 2-s2.0-56149103354 10.1371/journal.pone. 0003554 e3554
99. Blaauwgeers H. G. T., Holtkamp G. M., Rutten H., Witmer A. N., Koolwijk P., Partanen T. A., Alitalo K., Kroon M. E., Kijlstra A., Van Hinsbergh V. W. M., Schlingemann R. O., Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation. American Journal of Pathology 1999 155 2 421 428 2-s2.0-0032807809 (Pubitemid 29370392)
100. Schwarz Q., Gu C., Fujisawa H., Sabelko K., Gertsenstein M., Nagy A., Taniguchi M., Kolodkin A. L., Ginty D. D., Shima D. T., Ruhrberg C., Vascular endothelial growth factor controls neuronal migration and cooperates with SemaSA to pattern distinct compartments of the facial nerve. Genes and Development 2004 18 22 2822 2834 2-s2.0-8644219642 10.1101/gad.322904 (Pubitemid 39507774)
101. Sondell M., Lundborg G., Kanje M., Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. Journal of Neuroscience 1999 19 14 5731 5740 2-s2.0-0033565417 (Pubitemid 29327910)
102. Nishijima K., Ng Y. S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S. J., Robinson G. S., Adamis A. P., Shima D. T., Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. American Journal of Pathology 2007 171 1 53 67 2-s2.0-34547702738 10.2353/ajpath.2007.061237 (Pubitemid 47339226)
103. Kong L., Mintz-Hittner H. A., Penland R. L., Kretzer F. L., Chévez-Barrios P., pchevez-barrios@tmhs.org Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Archives of Ophthalmology 2008 126 8 1161 1163 10.1001/archophthalmol.2008.1